drugset / Trial / NCT07421232
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to compare the effectiveness, safety of SYH2053 in Participants with primary hypercholesterolemia or mixed dyslipidemia. A total of 156 Participants were actually enrolled
Timeline
- Start
- 2024-12-03
- Primary completion
- 2025-08-30
- Completion
- 2026-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Inclisiran | Small interfering RNA (siRNA) | 300 mg | Subcutaneous |
| Subject | SYH2053 | Unknown | — | Subcutaneous |